BACKGROUND: Sunitinib, used widely in metastatic renal cell carcinoma, can result in hypertension, left ventricular dysfunction, and heart failure. However, the relationships between vascular function and cardiac dysfunction with sunitinib are poorly understood.
S
everal VEGF (vascular endothelial growth factor) tyrosine kinase inhibitors have led to increases in progression-free and overall survival in the metastatic renal cell carcinoma (mRCC) population. [1] [2] [3] [4] [5] [6] [7] Sunitinib, an oral VEGF receptor-directed therapeutic agent with activity against all 3 VEGF receptors, PDGF (platelet-derived growth factor receptor) α and β, cKIT (stem cell factor receptor), and FLT3 (fms-like tyrosine kinase receptor 3), 8 is used as a first-line therapy for mRCC. 9 Unfortunately, these therapies are associated with significant cardiovascular toxicities as they also interfere with fundamental cardiovascular signaling pathways. VEGF tyrosine kinase inhibitors have been associated with hypertension, heart failure (HF), and left ventricular (LV) dysfunction. [10] [11] [12] [13] [14] Hypertension associated with VEGFinhibitor therapy is the most common cardiovascular side effect, with an estimated incidence of 19% to 47%. 15 LV dysfunction can also occur, and data from our own group, acquired through careful prospective cardiac monitoring, suggests that overall, 9.7% experience declines in LV ejection fraction (LVEF) of ≥10% to <50%. 16 LVEF declines tended to occur early, primarily within the first cycle (3.5 weeks) of exposure to sunitinib therapy. Despite the significance of this problem, detailed assessments and a comprehensive understanding of the effects of VEGF inhibitors on vascular function parameters are lacking. Although arterial blood pressure (BP) is often used clinically as a surrogate for LV afterload, LV afterload is actually a complex time-varying process determined by arterial stiffness and steady-state resistive and pulsatile load (Figures 1 and 2) . 17 The mechanical load imposed by the systemic circulation to the LV not only is a critical part of normal cardiovascular function but also plays an important role in the pathophysiology of various cardiac conditions, including hypertension, HF, and LV remodeling. Although it is speculated that the development of hypertension leads to LV dysfunction with sunitinib, the relationship between the development of sunitinibrelated hypertension and HF has not been precisely defined. 10, 12, 15, 18, 19 In this multicenter, longitudinal, prospective cohort study, we performed detailed noninvasive characterization of hemodynamic and arterial function among patients with mRCC receiving sunitinib and determined the relationships between the vasculature and LV function, using repeated measures derived from arterial tonometry and transthoracic echocardiography. A priori, we hypothesized that baseline and early changes in vascular function would be associated with LV dysfunction.
METHODS

Study Design
This was a multicenter prospective cohort study performed at the University of Pennsylvania, Vanderbilt University Medical Center, University of Wisconsin, University Hospitals Case Medical Center, and University of Utah Hospital. 16 Eligible participants were accrued between December 2011 and December 2015 and included patients with mRCC who planned to initiate sunitinib therapy. Sunitinib starting dose, schedule, and dose adjustments were determined at the discretion of the treating medical oncologist. All participants provided written informed consent, and the study protocol was approved by the institutional review board at each participating site.
Before the initiation of sunitinib, enrolled participants underwent a detailed review of their medical history, including cardiac events, cardiovascular risk factors, and current medications, with all findings verified by the oncology provider. All participants underwent a baseline transthoracic echocardiogram, BP assessment, and arterial tonometry.
Study follow-up was designed to detect both the peak and late incidences of LV dysfunction as a result of sunitinib exposure. 20 Accordingly, echocardiograms and arterial tonometry were performed at 3.5 weeks (±1 week), 15 weeks (±2 weeks), and 33 weeks (±2 weeks) after starting sunitinib. These follow-up visits coincided with cycles 1, 3, and 6 of sunitinib therapy, respectively, and were timed to occur while the participant was actively taking sunitinib. The decision to initiate antihypertensive or other cardiovascular medications was at the discretion of the treating medical provider. In the
WHAT IS NEW?
• This study is the first to comprehensively characterize the changes in vascular function in metastatic renal cell cancer patients receiving sunitinib therapy and to relate these to measures of left ventricular systolic and diastolic function.
• Sunitinib resulted in significant early increases in blood pressure, large artery stiffness, and resistive and pulsatile load within 3.5 weeks of therapy initiation.
• Changes in indices of vascular function observed with sunitinib were of significant magnitude, equivalent functionally to those observed over decades of aging of the arterial tree. Current antihypertensive therapies may attenuate these changes.
WHAT ARE THE CLINICAL IMPLICATIONS?
• Baseline measures of resistive and pulsatile load are associated with worse diastolic function and elevations in BNP (B-type natriuretic peptide) over time with sunitinib.
• Changes in vascular function occur within the first 3.5 weeks of sunitinib therapy, suggesting the critical importance of careful monitoring and treatment early within the first cycle of therapy initiation.
• Optimal antihypertensive therapies in the sunitinib-treated population may be those with arterial vasodilating properties and those with the ability to improve conduit artery function and central pulsatile hemodynamics.
event of sunitinib discontinuation because of disease progression or intolerable toxicity, follow-up cardiac assessments were obtained per protocol. The data, analytic methods, and study materials will not be made available to other researchers for purposes of reproducing the results or replicating the procedure.
Transthoracic Echocardiography
Transthoracic echocardiograms were performed at the participating sites according to a standardized protocol. Twodimensional images were acquired using the Philips IE33 platform (Andover, MA). Echocardiography quantification was independently performed in the imaging core laboratory at the University of Pennsylvania by trained sonographers blinded to patient characteristics and tonometry data. Quantification of end-systolic and end-diastolic LV volumes, LVEF, and diastolic function indices were performed using TomTec Image Arena (TomTec Imaging Systems, Unterschleissheim, Germany), as previously described 16, 21, 22 (Data Supplement). The E/e′ ratio was used as an estimate of diastolic function and LV filling pressures. LV outflow tract velocities were measured with pulsed-wave Doppler in the apical 5-chamber view. LV outflow tract cross-sectional area was computed from its diameter (d) measured in the parasternal long-axis view (area=π(d/2) 2 ). LV volume outflow (equal to aortic inflow) was computed as velocity times the cross-sectional area. Intraobserver coefficient of variation for LVEF was 4.4%. The intraobserver coefficient of variations for mitral inflow and tissue Doppler velocities were 2.3% to 5.4%.
Peak longitudinal systolic strain measurements were performed on digitally archived images on the TomTec Cardiac Performance Analyses (TomTec Imaging Systems, Unterschleissheim, Germany) as previously described 16, 23 (Data Supplement). Intraobserver coefficient of variation for longitudinal strain was 10.9%.
Arterial Tonometry and Assessment of Arterial Function
Arterial applanation tonometry was performed using a commercially available applanation tonometry system (SphygmoCor Vx System, AtCor Medical, Sydney, Australia) equipped with a high-fidelity Millar tonometer (SPT 301, Millar Instruments, Houston, TX) at the same time as the echocardiograms. Sites were required to submit qualification studies before patient enrollment, and quality control metrics were assessed real time with each study. Resting peripheral BP was also recorded using a validated oscillometric device (Omron HEM-705CP, Omron Corp, Kyoto, Japan). Arterial tonometry was performed at the radial, carotid, and femoral arteries. Radial tonometry waveforms were calibrated using oscillometric brachial systolic BP and diastolic BP. Mean arterial pressure was computed from the radial pressure waveform. Carotid tonometry waveforms were calibrated using mean arterial pressure and diastolic BP. Carotid-femoral pulse wave velocity (PWV) was measured with sequential carotid and femoral arterial tonometry, to compute the time delay between the 2 sites, using the QRS complex as a fiducial point. The distance between the suprasternal notch and the carotid recording point was subtracted from the distance between the sternal notch and the femoral recording point (femoral pulse to the umbilicus and then to the midline point of the suprasternal notch), and carotid-femoral PWV was calculated as distance/ change in time.
Vascular Hemodynamics
We used custom-designed software in MATLAB (R2014b; MathWorks, Natick, MA) to characterize arterial load, as previously described. [24] [25] [26] [27] [28] A trained operator assessed the reproducibility of beat-to-beat tonometry signals, the signal-averaged waveform, and evaluated all Doppler waveforms visually. Doppler waveforms were then digitized using semiautomated algorithms. A cardiologist experienced in pressure-flow analyses (J.A.C.) provided a final quality control (Methods section in the Data Supplement). Central pressure measurements were ensemble averaged and time aligned with LV outflow tract flow such that the upstroke of pressure and flow occurred simultaneously, peak flow was coincident with the first systolic peak or inflection point in the pressure waveform, and flow ceased at the dicrotic notch. Zc was quantified in the frequency domain as the average modulus at higher frequencies. Total peripheral resistance (TPR) was quantified as the ratio of mean pressure to mean flow. Total arterial compliance was determined using the pulse-pressure method. 24 Linear wave separation was performed to obtain the amplitude of the forward (P f ) and backward (P b ) pressure waves. Reflection magnitude was defined as the ratio of P b to P f (P b /P f ). [25] [26] [27] Reflected wave transit time was estimated via tube-load modeling. 27 Figures 1 and 2 illustrate the vascular function parameters derived from arterial tonometry and echocardiography. 17 Effective arterial elastance (E A ), a commonly used index of arterial load, was computed as the ratio of end-systolic pressure/stroke volume. E A depends on the interplay between systemic vascular resistance and heart rate, with negligible influence of pulsatile load. 28 After identification of the first (P1) and second (P2) systolic peaks in the central pressure waveform, augmentation index was computed as the augmented pressure (P2−P1) expressed as a percentage of central pulse pressure. Augmentation index is a composite measure dependent on several factors, including the magnitude and timing of wave reflections, and the LV ejection pattern.
Biomarker Analyses
Plasma samples were collected in EDTA tubes, processed at 3353 rpm for 20 minutes at room temperature, aliquoted, and stored at −80°C until the time of assay. BNP (B-type natriuretic peptide) was quantitatively measured using the Singulex Single Molecule Counting laboratory assay (Alameda, CA).
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Statistical Analysis
Baseline patient characteristics were described using counts and percentages for categorical variables and medians and interquartile ranges for continuous variables. Baseline vascular function parameters were also described using medians and interquartile ranges. Longitudinal trends in vascular function measures were assessed using piecewise linear regression with confidence intervals (CI) estimated using robust (HuberWhite) sandwich-based SEs [30] [31] [32] to illustrate the mean trend in vascular function measures across visits. For BP and all vascular function parameters, the mean changes from visit 1 to visit 2 and the 95% CI were computed. Hypothesis tests for change from visit 1 to visit 2 were conducted using 1-sample t tests. These changes were also evaluated in a subgroup of participants who did not have any new antihypertensive therapy initiated between visits 1 and 2. The effect of adjustment for heart rate and mean arterial pressure on these changes was also explored.
The relationship between baseline vascular function measures and change in LVEF at each visit relative to baseline was examined using linear regression models estimated via generalized estimating equations with an independence working correlation structure to account for within-subject correlation. 33 The independence working correlation was chosen to avoid the possibility of bias, which may be induced when using more complex working correlation structures. 34 Unadjusted models included visit number and individual vascular function variables. Adjusted models additionally included age and sex. To allow for comparison of the presented relationships, vascular function measures were scaled by their SD. Therefore, reported parameter estimates represent estimated average difference in the change in LVEF relative to baseline associated with a 1 SD increase in a given vascular function measure. Unadjusted and adjusted regression models were also estimated for longitudinal strain, E/e′, and log 10 BNP (outcome measure) using generalized estimating equations, with a separate regression model estimated for each combination of outcome measure and vascular function measure. BNP was log transformed given its skewed distribution. The associations between changes in vascular function measures between visit 1 and visit 2 and changes in outcome measures (LVEF, longitudinal strain, E/e′, and log 10 BNP) between visit 1 and visit 2 and, separately, between visit 1 and visit 3 were estimated using linear regression.
All statistical analyses were conducted using R 3.4.0 (R Foundation for Statistical Computing, Vienna, Austria). Statistical significance was evaluated at a 2-sided α of 0.05 level.
RESULTS
Patient Population
This study consisted of 84 patients who were prospectively enrolled before initiation of sunitinib therapy and underwent baseline echocardiography and arterial tonometry. Baseline characteristics are summarized in Table 1 . The median age was 62.5 years (interquartile range, 55.8-68.0). Hypertension (55%) and hyperlipidemia (52%) were highly prevalent at baseline, as was the use of antihypertensive therapy, although no patients were treated with nitrates. Baseline BP measurements and vascular parameters are shown in Table 2 .
The median follow-up time was 30.9 weeks (interquartile range, 6.3-35.0 weeks). Of the 84 participants enrolled at baseline, 92% had follow-up echocardiography and tonometry at 3.5 weeks (visit 1/cycle 1), 69% at 15 weeks (visit 3/cycle 3), and 51% at 33 weeks (visit 4/cycle 6). The decrease in participants over time was primarily secondary to progressive oncological disease.
Changes in BP With Sunitinib Over Time
Overall, and as expected, significant increases in BP occurred early (Table 2 ; Figure 3 ). Between baseline 
Changes in Vascular Function With Sunitinib Over Time
Vascular function parameters are shown across all visits in Figure 3 , with the most pronounced changes noted between visit 1 and visit 2. The mean changes and 95% CIs in various vascular function indices between baseline and 3.5 weeks are further detailed in Table 2 . Across all participants, carotid-femoral PWV increased significantly by 0.7 m/s (95% CI, 0.4-1.1). This finding was independent of adjustment for HR and mean arterial pressure (adjusted mean change, 0.7 m/s; 95% CI, 0.3-1.0). Resistive load indices also increased with sunitinib. TPR demonstrated a mean increase of 640.0 dyn·sec·cm −5 (95% CI, 346.7-920.0) and effective E A increased by 0.6 mm Hg/mL (95% CI, 0.3-0.8).
Pulsatile load, characterized by total arterial compliance and measures of wave reflection, also showed significant changes, providing additional evidence for adverse vascular function. There was a notable reduction in total arterial compliance with a mean change of −0.3 mL/mm Hg (95% CI, −0.5 to −0.2). Although early systolic pulsatile load, defined by aortic impedance (Zc), did not significantly change, measures of wave reflection did demonstrate significant changes. Augmentation index increased by 6.9% (95% CI, 2.4-11.5), and reflected wave transit time decreased by 7.4 ms (95% CI, −13.1 to −1.7).
We also explored the impact of changes in BP medications on changes in vascular function parameters. Participants who newly initiated antihypertensive medications, on average, had an attenuation of the changes in vascular function parameters observed between visits 1 and 2, compared with the subgroup who did not initiate new medications. Although measures of peripheral BP were similar between the 2 groups, changes in resistive and pulsatile load qualitatively seemed to be more pronounced in those who did not start new antihypertensive medications, although there was no statistically significant interaction (Table I in the Data Supplement).
Relationship Between Baseline Vascular Function Measures and LV Systolic Function Over Time
Next, the relationship between vascular function at baseline as it related to LV systolic function, specifically LVEF and longitudinal strain were assessed over time. As previously reported, 16 we found an overall 9.7% risk of developing LV dysfunction (LVEF decline ≥10% to a value of <50%) in this study. The majority of patients of those who developed LV dysfunction did so within 3.5 weeks after initial sunitinib treatment. On average, there was a significant but modest Figure 3A) .
There was no significant relationship between baseline vascular function, including markers of both resistive and pulsatile load, and change in LVEF over time in adjusted (Table 3 ) and unadjusted analyses (data not shown). Similarly, no significant association was observed between baseline measures and longitudinal strain over time (Table 4) . Early changes in vascular parameters between baseline (visit 1) and 3.5 weeks (visit 2/cycle 2) after initiation of sunitinib were not associated with changes in LVEF or longitudinal strain over the same time interval or subsequent visit at 15 weeks (visit 3/cycle 6; Tables II through V in the Data Supplement). 
Relationship Between Baseline Vascular Function Measures and LV Diastolic Function and BNP Over Time
Next, we estimated the relationship between baseline vascular function and changes in a surrogate marker of diastolic function and LV filling pressures (E/e′) during sunitinib treatment (Table 5) . Resistive load at baseline, as assessed by TPR and E A , was associated with increased E/e′ after the initiation of sunitinib. Each SD change in baseline TPR was associated with a 0.8-U increase in E/e′ from baseline to visit 2 (95% CI, 0.2-1.4; P=0.01). For each SD increase in E A at baseline, there was a 0.9-U increase in E/e′ from baseline to visit 2 (95% CI, 0.3-1.5; P=0.004). Similarly, aortic root impedance (Zc), a measure of the pulsatile load imposed by the aortic root (P<0.001), and augmentation pressure were associated with increased E/e′ over time (P=0.01). Significant associations were also observed between baseline vascular function (E A and Zc) and log 10 BNP (Table 5) . However, early changes in vascular parameters between baseline (visit 1) and 3.5 weeks (visit 2/cycle 2) after initiation of sunitinib were not consistently associated with changes in diastolic function (E/e′ and log 10 BNP) over the same time interval or subsequent visit at 15 weeks (visit 3/ cycle 6; Tables VI through IX in the Data Supplement).
DISCUSSION
VEGF-inhibitor therapies including sunitinib are associated with significant adverse cardiovascular effects, namely, hypertension, LV dysfunction, and HF. [10] [11] [12] [13] [14] However, detailed relationships between vascular function parameters and hypertension and LV dysfunction have not been specifically studied. To our knowledge, this is the first prospective study performed using serial echocardiography including systolic and diastolic function assessment, longitudinal biomarkers, and repeated measures derived from arterial tonometry to comprehensively characterize cardiotoxicity with exposure to sunitinib in mRCC patients.
Our study demonstrated several important findings. First, vascular function in this mRCC cohort worsened early; increases in large artery stiffness with sunitinib were observed within the first 3.5 weeks of therapy. Second, we demonstrated worsening in both resistive and pulsatile load after initiation of sunitinib, similar to sorafenib. 35 Our study extends these findings through a more detailed assessment of vascular function, beyond PWV and augmentation index alone. Third, we found no significant associations between vascular function measures and LV systolic function (LVEF or longitudinal strain), although vascular function was associated with diastolic function and filling pressures (E/e′ and BNP).
Total peripheral resistance and E A , markers of resistive load, showed significant increases with sunitinib. TPR is determined by the number and caliber of arterioles, in contrast to pulsatile load, which is more closely linked to the properties of conduit arteries. Decreased NO production, increased endothelin-1 production, and microvascular rarefaction have been proposed as possible mechanisms for VEGF-inhibitor-related hypertension. 15, 18 Microvascular rarefaction is a process of endothelial cell apoptosis and remodeling of the capil- lary beds, eventually leading to diminished number of microvessels. 36 Increased resistive load demonstrated in our study supports the hypothesis that microvascular rarefaction may have a role in the pathophysiology of sunitinib-related hypertension.
We found significant increases in carotid-femoral PWV, suggesting worsening large artery stiffness. Although it has been speculated that hypertension itself leads to increasing arterial stiffness, arterial stiffness may actually represent the cause rather than the consequence of isolated systolic hypertension. 37 Data from the Framingham Heart Study found that increased PWV preceded development of hypertension by 7 years. 37 Given the rapid changes in arterial stiffness and hypertension we observed, increasing arterial stiffness is likely involved in the pathophysiology of hypertension induced by sunitinib and other VEGF inhibitors.
Increasing arterial stiffness has been demonstrated to be an independent risk factor for coronary and cerebrovascular disease, 9,10 as well as diastolic and systolic LV dysfunction. 38, 39 Measures of pulsatile load include the aortic root Zc, measures of wave reflection magnitude and timing, and the total compliance of the arterial tree. 40, 41 Aortic root Zc, the main determinant of early systolic pulsatile load, is dependent on the elastic properties of the aorta and governs the pressure-flow relation in the absence of wave reflections. 41, 42 The load imposed by wave reflections depends on complex physical properties (stiffness, taper, and branching) of the arterial tree, PWV and the distance to reflection sites, and the reflected wave transit time from the heart to the periphery and back. 40, 41, 43 In our study, Zc was only minimally increased while augmentation index increased more significantly, likely representing the effects of premature wave reflections, as supported by reduction in reflected wave transit time. Augmentation of reflected pressure waves results in an increase in mid to late systolic load of the LV. 41 This pattern of late systolic load has been shown to lead to myocardial hypertrophy, 44, 45 fibrosis, 41 LV systolic and Vascular function variables scaled by their SDs, and regression coefficients are multiplied by 100 and adjusted for age, sex, and categorical visit number. For example, each SD increase in SBP was associated with a nonsignificant 0.2% increase in LVEF (P=0.64). Repeated measures accounted for using GEE. AI indicates augmentation index; CI, confidence interval; DBP, diastolic blood pressure; E A , effective arterial elastance; GEE, generalized estimating equation; LVEF, left ventricular ejection fraction; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic blood pressure; TAC, total arterial compliance; TPR, total peripheral resistance; and Zc, aortic characteristic impedance. diastolic dysfunction, 39, [46] [47] [48] and HF. 49 The reduction in total arterial compliance observed in just a short period with sunitinib therapy is equivalent to observed changes over decades of aging of the arterial tree in the general population, 25 although it may be largely functional. We identified important relationships between baseline vascular function and worsening diastolic function and elevations in BNP over time with sunitinib treatment. We showed that increased pretreatment TPR, E A , Zc, and augmentation pressure, representative of resistive and pulsatile load (both early and late systolic load) were each associated with worsening diastolic function. There was also a significant relationship between BNP and E A and Zc. This relationship between arterial stiffness and diastolic dysfunction and elevated filling pressures because of abnormal load and loading sequence is well recognized. 38, 39 However, our study is the first to demonstrate this with VEGF inhibitors. Moreover, these findings suggest that baseline assessment of vascular function indices can result in an improved understanding of cardiovascular risk.
Given the associations between baseline measures of abnormal resistive load and arterial compliance with worsening diastolic function over time, we hypothesize that ideal antihypertensive therapies in sunitinib-treated patients may be those with arterial vasodilating properties and the ability to improve conduit artery function, such as a combination of calcium channel blockers and inorganic nitrates. By improving muscular artery compliance, the phase of reflected waves could be shifted to reduce the late systolic load by wave reflections. As selective vasodilators of conduit arteries, inorganic nitrates may be ideal agents to mitigate these effects in the sunitinib-treated population. 50 Dihydropyridine calcium channel blockers that affect resistive load may also be effective in this population, and clinical experience supports this. In contrast, pure β-blockers may be less preferred given prolongation in ejection time, which may increase vulnerability to reflected waves. Of note, of the 23 patients prescribed a β-blocker, the majority (19/23) were treated with a pure β-blocker. The role of these agents, and of noninvasive hemodynamic testing to personalize therapy in this clinical setting, should be assessed in future trials.
Contrary to our hypothesis, measures of vascular function were not associated with LV systolic func- Vascular function variables scaled by their SDs. Regression coefficients adjusted for age, sex, and categorical visit number. Repeated measures accounted for using GEE. AI indicates augmentation index; BNP, B-type natriuretic peptide; CI, confidence interval; DBP, diastolic blood pressure; E A , effective arterial elastance; GEE, generalized estimating equation; LV, left ventricular; MAP, mean arterial pressure; PP, pulse pressure; PWV, pulse wave velocity; SBP, systolic blood pressure; TAC, total arterial compliance; TPR, total peripheral resistance; and Zc, aortic characteristic impedance.
tion. Our small sample size may have limited our ability to demonstrate a relationship between increased arterial stiffness and the subsequent development of systolic dysfunction, as assessed by LVEF and longitudinal strain. The population average changes in LVEF were also relatively modest, on the order of −1.9%, which likely also limited our ability to detect a significant association. 16 Moreover, we were unable to investigate associations with the categorical outcome of LV dysfunction or changes over the long term given limitations in power. We focused on E/e′ as a surrogate of diastolic function and LV filling pressures but acknowledge that a comprehensive assessment of diastolic function includes multiple additional parameters. An observed lack of association may also be related to the effect of medications. At baseline, 55% of patients had hypertension and 52% of patients were treated with antihypertensive therapy. At the first follow-up visit after sunitinib therapy (visit 2), 50% of patients were treated with antihypertensive therapies, and these agents attenuated the changes in vascular function (Table I in the Data Supplement) .
In conclusion, we demonstrated that sunitinib therapy in mRCC patients is associated with increased large artery stiffness and resistive and pulsatile load within 3.5 weeks of treatment. Although we did not find an association between changes in vascular function parameters and LV systolic dysfunction as originally hypothesized, we did demonstrate a significant association with worsening diastolic dysfunction (E/e′) and LV filling pressures (BNP) and change in vascular function over time. Our study offers insight into the complex time-varying process of vascular function in the setting of VEGF inhibitor therapy. Moreover, our findings emphasize the importance of phenotypic characterization of the changes in vascular function parameters with therapies that affect BP.
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